Amryt Pharma (Amryt Pharma) 3-Year Dividend Growth Rate : 0.00% (As of Sep. 2022)

View and export this data going back to 2019. Start your Free Trial

What is Amryt Pharma 3-Year Dividend Growth Rate?

Amryt Pharma's Dividends per Share for the three months ended in Sep. 2022 was $0.00.

The historical rank and industry rank for Amryt Pharma's 3-Year Dividend Growth Rate or its related term are showing as below:

AMYT's 3-Year Dividend Growth Rate is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 11
* Ranked among companies with meaningful 3-Year Dividend Growth Rate only.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Amryt Pharma's Dividend Payout Ratio for the three months ended in Sep. 2022 was 0.00. As of today, Amryt Pharma's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Amryt Pharma's 3-Year Dividend Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Amryt Pharma's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Amryt Pharma's 3-Year Dividend Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amryt Pharma's 3-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where Amryt Pharma's 3-Year Dividend Growth Rate falls into.

Amryt Pharma 3-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Amryt Pharma (NAS:AMYT) 3-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Amryt Pharma's Dividend Payout Ratio for the quarter that ended in Sep. 2022 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Sep. 2022 )	/	EPS without NRI (Q: Sep. 2022 )
	=	0	/	-0.3
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amryt Pharma 3-Year Dividend Growth Rate Related Terms>

Amryt Pharma (Amryt Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amryt Pharma PLC (NAS:AMYT) » Definitions » 3-Year Dividend Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

196 High Road, Dept 920A, Wood Green, London, GBR, N22 8HH

Website

http://www.amrytpharma.com

Amryt Pharma PLC is a specialty pharmaceutical company. It is focused on developing and delivering new treatments to help improve the lives of patients with rare or orphan diseases. It holds an exclusive license to sell Lojuxta (lomitapide) for adults, across the European Union and other territories including the Middle East, North Africa, Turkey and Israel. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia. Myalept (metreleptin) is an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients. It derives most of the revenue from the European Economic Area (EEA).